Sign Up
Stories
BioSenic's Phase 3 Study for Chronic GvHD
Share
Advancements in Cancer Treatment and Mar...
AnaMar Receives Orphan Drug Designation ...
Autolus Thrives with $350M Offering and ...
ADOCIA Files 2023 Registration Document
ANJESO Drug Insight and Market Forecast
Acquisition Progress Amid Safety Concern
Overview
API
BioSenic, a clinical-stage company, is set to attend the GvHgvL Meeting to discuss a Phase 3 study of its oral arsenic trioxide therapy for chronic GvHD. The company plans to enroll about 150 patients across three continents this year. BioSenic's CEO emphasized the potential value of this therapy and highlighted the company's focus on developing products in two tracks: immunomodulatory properties of arsenic trioxide for anti-inflammatory and anti-autoimmune indications and cell therapies for tissue repair technologies.
Ask a question
How could BioSenic's therapy be adapted for use in other autoimmune or inflammatory diseases?
How might BioSenic's oral arsenic trioxide therapy impact the treatment landscape for chronic GvHD?
What are the potential implications of BioSenic's focus on developing products in two tracks: immunomodulatory properties and cell therapies for tissue repair?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Jan 2024
Coverage